Shanghai - Delayed Quote
CNY
Beijing Konruns Pharmaceutical Co.,Ltd. (603590.SS)
24.81
-1.73
(-6.52%)
At close: October 30 at 3:00:01 PM GMT+8
Key Executives
Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CNY.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Zhanqi Niu
|
President & Director | -- | -- | 1967 |
|
Mr. Xiaohan Liu
|
CFO & Director | -- | -- | 1988 |
|
Mr. Xiao Dong Huang
|
Secretary to the Board | -- | -- | 1971 |
|
Jing Wang
|
Accounting Supervisor | -- | -- | -- |
Beijing Konruns Pharmaceutical Co.,Ltd.
Building 3, No. 7 Science Park Road
Zhongguancun Life Science Park Changping District
Beijing, 102206
China
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 793
Description
Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. The company offers agkistrodon halys hemocoagulase under Suling trade name. It is also involved in the development of drug candidates, including ZY5301 that is in phase 3 clinical trials for the treatment of chronic pelvic pain in sequelae of pelvic inflammatory disease; and KC1036, which is in phase 2 clinical trial for the treatment of solid tumors. The company was founded in 2003 and is headquartered in Beijing, China.
Corporate Governance
Beijing Konruns Pharmaceutical Co.,Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of
Institutional Shareholder Services (ISS)
Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
July 8, 2026 at 12:00 AM UTC
Ex-Dividend Date
